证券代码：600566 证券简称：济川药业 公告编号：2025-087

Core Points - The company has announced the listing of 1,630,800 shares as part of its equity incentive plan, with the shares set to become tradable on September 30, 2025 [1][9] - The board of directors has confirmed that the conditions for the first unlock period of the restricted stock have been met, allowing 58 eligible participants to unlock their shares [7][8] Summary of the Incentive Plan - The incentive plan was approved through a series of meetings, starting from August 1, 2022, with the final approval from the shareholders on August 22, 2022 [2][3] - The first grant of restricted stock and stock options was registered on September 27, 2022, and the first unlock period is set to end on September 26, 2025 [7][9] - The total number of shares eligible for unlock is 1,630,800, which represents 0.18% of the company's total share capital [8] Unlocking and Trading Arrangements - The unlocking of shares will occur on September 30, 2025, with specific restrictions on the transfer of shares by directors and senior management during their tenure and for six months post-departure [9] - The company will repurchase and cancel any shares that do not meet the unlocking conditions [7][9] Legal Compliance - The company has confirmed that the unlocking and exercise of options comply with relevant laws and regulations, including the Company Law and Securities Law [9][10]